These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 16475674

  • 1. Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.
    Leto G, Badalamenti G, Arcara C, Crescimanno M, Flandina C, Tumminello FM, Incorvaia L, Gebbia N, Fulfaro F.
    Anticancer Res; 2006; 26(1A):23-6. PubMed ID: 16475674
    [Abstract] [Full Text] [Related]

  • 2. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
    Tumminello FM, Flandina C, Crescimanno M, Leto G.
    Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
    [Abstract] [Full Text] [Related]

  • 3. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L, Badalamenti G, Rini G, Arcara C, Fricano S, Sferrazza C, Di Trapani D, Gebbia N, Leto G.
    Anticancer Res; 2007 Feb; 27(3B):1519-25. PubMed ID: 17595770
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA.
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Sep; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 12. Matrix metalloproteinase-9 expression in alveolar extraction sockets of Zoledronic acid-treated rats.
    Basi DL, Hughes PJ, Thumbigere-Math V, Sabino M, Mariash A, Lunos SA, Jensen E, Gopalakrishnan R.
    J Oral Maxillofac Surg; 2011 Nov; 69(11):2698-707. PubMed ID: 21752506
    [Abstract] [Full Text] [Related]

  • 13. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase-9 in nonsmall cell lung cancer patients.
    Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP, Chu SC.
    Clin Chim Acta; 2005 Apr; 354(1-2):91-9. PubMed ID: 15748604
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 May; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Amir E, Trinkaus M, Simmons CE, Dranitsaris G, Clemons MJ.
    J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
    [Abstract] [Full Text] [Related]

  • 20. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D, Nikolaou M, Farmakis D, Kanakis I, Gaglia A, Kountourakis P, Karamanos NK, Economopoulos T, Raptis SA.
    Anticancer Res; 2005 May; 25(2B):1457-63. PubMed ID: 15865105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.